Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18,

Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascen

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raise

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 –

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 –

Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company

Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Pre

Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's

Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m

Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appea

Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appea

Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithi

Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithi

Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company

Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain

Shares of Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) dropped 2.5% on Monday. The stock tr

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lower

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.30) per share which beat the analyst c

Alzamend Neuro, Inc. (NASDAQ: ALZN - Get Free Report) shares were down 0.5% on Friday. The company t

Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithi

Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for bette

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowe

Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lower

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, an

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million St

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clini

Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate

Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate p

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate

Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comp

After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), in

ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clin

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment o

ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clin